

# THE IMPACT OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION

While chemotherapy remains the cornerstone of treatment for most cancers, it does not differentiate between healthy cells and cancer cells—it damages both, including important stem cells in the bone marrow. These stem cells normally develop into healthy red blood cells, white blood cells, and platelets.<sup>1-3</sup>

APPROXIMATELY

# 1M

## Patients receive chemotherapy annually<sup>12</sup>

## SYMPTOMS, SIDE EFFECTS, AND COMPLICATIONS

Myelosuppression may cause a range of potential side effects, which may then stress patients and the healthcare system.

Myelosuppression puts patients at increased risk of **infection, anemia, fatigue, and bleeding**<sup>3-6</sup>



Immune cell damage may decrease the ability of the immune system to fight cancer and infections<sup>2,11</sup>



Myelosuppression may require the administration of rescue interventions, such as **growth factors, blood transfusion, and platelet transfusion**<sup>4,7-9,11</sup>




This side effect can result in dosage delays and reductions, which may **compromise the efficacy of chemotherapy regimens** and burden the healthcare system<sup>8,10,11</sup>

## WHAT IS MYELOSUPPRESSION?


A sometimes serious side effect in chemotherapy, myelosuppression is the result of damage to bone marrow stem cells. Myelosuppression can adversely affect patient health and quality of life and may compromise treatment outcomes.<sup>3,6,11</sup>

## REAL-WORLD IMPACT


Myelosuppression can have a substantial impact on people's lives and treatment:



In an online survey of 301 patients with solid tumors, **nearly 9 in 10 (88%) patients** reported that myelosuppression has a moderate to major impact on their quality of life<sup>11</sup>



**Nearly 2 in 3 patients (64%)** reported chemotherapy dose modifications (delays, reductions, discontinuation) due to myelosuppression<sup>11</sup>



**Nearly 1 in 3 patients (30%)** felt their oncologist did not understand their discomfort caused by myelosuppression<sup>11</sup>

## MANAGING MYELOSUPPRESSION

Patients experiencing myelosuppression may be treated with medication adjustments, supportive care, and rescue interventions as needed.

**REFERENCES:** 1. Halpern MT, Yabroff KR. Prevalence of outpatient cancer treatment in the United States: estimates from the medical panel expenditures survey (MEPS). *Cancer Invest.* 2008;26(6):647-651. 2. American Cancer Society. Chemotherapy side effects. Accessed January 19, 2021. <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html> 3. Barreto JN, McCullough KB, Ice LL, Smith JA. Antineoplastic agents and the associated myelosuppressive effects: a review. *J Pharm Pract.* 2014;27(5):440-446. 4. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. *Oncol.* 2015;29(4):282-294. 5. Taylor SJ, Duyvestryn JM, Dagger SA, et al. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. *Sci Transl Med.* 2017;9(402):1-13. 6. Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. *Int J Clin Transfusion Med.* 2018;6:21-31. 7. Aapro M, Beguin Y, Bokemeyer C, et al; ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Ann of Oncol.* 2018;29(suppl 4):iv96-iv110. 8. Crawford J, Denduluri N, Patt D, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. *Support Care Cancer.* 2020;28:925-932. 9. Klastersky J, de Naurois J, Rolston K, et al; ESMO Guidelines Committee. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann of Oncol.* 2016;27(suppl 5):v111-v118. 10. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer.* 2004;100(2):228-237. 11. Epstein RS, Aapro MS, Basu Roy UK, et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors. *Adv Ther.* 2020;37(8):3606-3618. 12. Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. *Lancet Oncol.* 2019;20:769-780. [https://doi.org/10.1016/S1470-2045\(19\)30163-9](https://doi.org/10.1016/S1470-2045(19)30163-9)